FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management

Dockets Entered On June 28, 2006
Table of Contents
Docket # Title
1995V-0105 Laser Light Show
1996V-0432 Laser light show application
2002V-0183 Laser Light Show
2003V-0426 Laser Light Show
2005P-0008 simvastatin tablets 5mg, 10mg, 20mg, and 40 mg
2005P-0046 removal of patent listings by reinserting the info in the orange book and maintain the listing until Ranbaxy's term of exclusivity has elapsed
2005P-0072 Withholding of safety information regarding risks of Steven s Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Ibuprofen products
2005P-0323 Immediately remove Adderall and Adderall XR from the market for safety reasons
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
2005P-0509 Evaluation the warning to Consumers that Psychosis Is a possible adverse effect of Keppra (levetiracetam)
2005V-0368 Projector for a Laser Light Show for Flare F1-1104; Flint: F2-0104; Firefly : F3-0905
2006D-0254 Guidance for Industry: Analytical Methods Description for Type C Medicated Feeds
2006D-0268 Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
2006N-0133 Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of Variations in Content and Format of the Brief Summary in Direct-to-Consumer (DTC) Print Adver
2006P-0001 Date of Approval for Lunesta (Eszopiclone) Tablets
2006P-0047 Refrain from Approval any ANDA for Celestone Soluspan
2006P-0241 Appeal District Court Civil Action No. 05-1838 (RWR) and deny the citzen petitions of Ivax and Ranbaxy
2006P-0258 Immediately approve ANDA No. 77-837 upon the June 23, 2006 patent expiration of U.S. Patent No. 4,444,784
2006V-0111 Projector for a Laser Light Show
2006V-0153 Variance for Hair Removal System
2006V-0155 Laser Light Show
2006V-0248 Laser Light Show
1995V-0105 Laser Light Show
VRA 6 FDA/CDRH to Stellar Designs, Inc. Vol #: 1
1996V-0432 Laser light show application
VRA 3 FDA/CDRH to N Effect Production Vol #: 1
2002V-0183 Laser Light Show
CR 1 FDA/DDM to Funzalosound Vol #: 1
2003V-0426 Laser Light Show
VRA 3 FDA/CDRH to Celebration City Vol #: 1
2005P-0008 simvastatin tablets 5mg, 10mg, 20mg, and 40 mg
LET 3 FDA/CDER to Ivax Pharmaceuticals, Inc. Vol #: 2
2005P-0046 removal of patent listings by reinserting the info in the orange book and maintain the listing until Ranbaxy's term of exclusivity has elapsed
LET 2 FDA/CDER to Buc and Beardsley Vol #: 2
2005P-0072 Withholding of safety information regarding risks of Steven s Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Ibuprofen products
PAV 1 FDA/CDER to New York Medical College, Vol #: 1
2005P-0323 Immediately remove Adderall and Adderall XR from the market for safety reasons
C 1 D. Lowe Vol #: 1
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
C 13755 S. Bondroff Vol #: 158
C 13756 C. Lewis Vol #: 158
C 13757 B. G. Wright Vol #: 158
C 13758 J. P. Orr Vol #: 158
C 13759 L. A. Weis Vol #: 158
C 13760 R. Smith Vol #: 158
C 13761 J. Lee, M.D. Vol #: 158
C 13762 S. W. Aaron Vol #: 158
C 13763 A. M. Henley Vol #: 158
C 13764 J. Houck Vol #: 158
C 13765 V. L. Poels Vol #: 158
C 13766 J. Norman Vol #: 158
C 13767 J. Blackwell Vol #: 158
C 13768 P. Greene Vol #: 158
C 13769 T. Tuten Vol #: 158
C 13770 A. S. Wright Vol #: 158
C 13771 G. Hoffmann Vol #: 158
C 13772 H. I. Hopkins Vol #: 158
C 13773 M. Westmoreland Vol #: 158
C 13774 M. Cashatt Vol #: 158
C 13775 N. C. Stone Vol #: 158
C 13776 E. Goheen Vol #: 158
C 13777 W. B. Timmerman Vol #: 158
C 13778 D. Harris Vol #: 158
C 13779 L. A. Dixon Vol #: 158
C 13780 C. C. Marshall Vol #: 158
C 13781 S. W. Best Vol #: 158
C 13782 J. Fitts Vol #: 158
C 13783 D. Glenn Vol #: 158
C 13784 A. A. Acosta Vol #: 158
C 13785 S. Gates Vol #: 158
C 13786 M. Beatty Vol #: 158
C 13787 P. Cummings Vol #: 158
C 13788 E. Massey Vol #: 158
C 13789 S. J. Wrenn Vol #: 158
C 13790 M. E. Wesley Vol #: 158
C 13791 D. P. Warren Vol #: 158
C 13792 Joh R. Warren Vol #: 158
C 13793 F. Liberson Vol #: 158
C 13794 D. Kirkham Vol #: 158
C 13795 C. Tillinglast Vol #: 158
C 13796 W. Kensinger Vol #: 158
C 13797 J. Jurcy Vol #: 158
C 13798 L. J. Garrison Vol #: 158
C 13799 J. L. Garrison Vol #: 158
C 13800 P. Kopit Vol #: 158
C 13801 S. Alexander Vol #: 158
C 13802 S. Kirk Vol #: 158
C 13803 M. V. Roekel Vol #: 158
C 13804 P. Nodler Vol #: 158
C 13805 M. A. Campbell Vol #: 159
C 13806 J. Fairleigh Vol #: 159
C 13807 C. Vickery Vol #: 159
C 13808 L.Ritter Vol #: 159
C 13809 D. Lett Vol #: 159
C 13810 L. Ritter Vol #: 159
C 13811 V. Barney Vol #: 159
C 13812 R. Bailey Vol #: 159
C 13813 N. Clausen Vol #: 159
C 13814 M. Bennett Vol #: 159
C 13815 D. Jacobson Vol #: 159
C 13816 D. Martin Vol #: 159
C 13817 N. Clausen Vol #: 159
C 13818 Y. Lass Vol #: 159
C 13819 W. Bernard Vol #: 159
C 13820 Mrs. J. Gaughan Vol #: 159
C 13821 G. Stevens Vol #: 159
C 13822 P. Lee Vol #: 159
C 13823 J. G. Gervais Vol #: 159
C 13824 C. Jantzen Vol #: 159
C 13825 C. Van Poznak Vol #: 159
C 13826 K. LaCroix Vol #: 159
C 13827 M. Robinson Vol #: 159
C 13828 L. Sinnwell Vol #: 159
C 13829 J. Anderson Vol #: 159
C 13830 K. Yonkers Vol #: 159
C 13831 K. Kendall Vol #: 159
C 13832 L. Wilson Vol #: 159
C 13833 S. Wanamaker Vol #: 159
C 13834 J. Hunerberg Vol #: 159
C 13835 K. S. Fabian Vol #: 159
C 13836 J. Berman Vol #: 159
C 13837 S.C. Skolnikoff, Ph.D. Vol #: 159
C 13838 J. Smith Vol #: 159
2005P-0509 Evaluation the warning to Consumers that Psychosis Is a possible adverse effect of Keppra (levetiracetam)
LET 1 FDA/CDER to Warren Rucker Vol #: 1
2005V-0368 Projector for a Laser Light Show for Flare F1-1104; Flint: F2-0104; Firefly : F3-0905
VRA 1 FDA/CDRH to Prismatic Magic LLC Vol #: 1
2006D-0254 Guidance for Industry: Analytical Methods Description for Type C Medicated Feeds
GDL 1 Guidance Vol #: 1
NAD 1 FDA Vol #: 1
2006D-0268 Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
C 1 R. Reinhard Vol #: 1
2006N-0133 Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Evaluation of Variations in Content and Format of the Brief Summary in Direct-to- Consumer (DTC) Print Adver
C 3 AstraZeneca Pharmaceuticals, LP Vol #: 1
2006P-0001 Date of Approval for Lunesta (Eszopiclone) Tablets
C 1 D. Lowe Vol #: 1
2006P-0047 Refrain from Approval any ANDA for Celestone Soluspan
PAV 1 FDA/CDER to SPEC Pharma Vol #: 1
2006P-0241 Appeal District Court Civil Action No. 05-1838 (RWR) and deny the citzen petitions of Ivax and Ranbaxy
LET 1 FDA/CDER to Pollack PC Vol #: 1
2006P-0258 Immediately approve ANDA No. 77-837 upon the June 23, 2006 patent expiration of U.S. Patent No. 4,444,784
LET 1 FDA/CDER to Pollack PC Vol #: 1
2006V-0111 Projector for a Laser Light Show
VRA 1 FDA/CDRH to Aurora Projections Vol #: 1
2006V-0153 Variance for Hair Removal System
VRA 2 FDA/CDRH to Palomar Medical Technologies, Inc. Vol #: 1
2006V-0155 Laser Light Show
VRA 1 FDA/CDRH to Club Rabie, Inc Vol #: 1
2006V-0248 Laser Light Show
VRA 1 FDA/CDRH to Independence High-SpaceScience Tech Magnet Vol #: 1

Page created on July 27, 2006 kk

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management